CANImmunize

48
CANImmunize
CANImmunize is an Android app from CANImmunize Inc. in the Medical category, currently rated 3.3★ across 1,067 ratings. Initial signal reads as mostly critical sentiment so far: users flag rough edges and unmet expectations.
Quality Score is 48: Emerging (early traction worth watching). For a Medical app, that means early traction worth watching. The full BU Investment Matrix below scores 8 dimensions including monetisation, growth, and operational risk.
Track changes month-over-month in the Performance section below: live snapshot history and revenue forecast included.
- Title & subtitle keyword fit
- Description hook & conversion structure
- Screenshots, ratings, reviews strategy
📊 Performance Tracking LIVE
Synthetic estimate. Inputs: category complexity, file size, screen count, monetization layer, platform reach, age × team-size proxy. Calibrated against 2024-2026 indie-agency rate surveys. Full math + source list on /methodology.
| 🧱 MVP baseline (design + 1-store ship) | +$28K |
| 📱 5 unique screens × $4.5K | +$22K |
| ⚙ Medical complexity ×1.55 | +$27K |
| 🌐 Cross-platform reach (iOS + Android) | +$43K |
Synthetic estimate. Multiple band derived from ad-supported + age, rating quality, category demand, and user-base maturity. Calibrated against 2024-2026 indie-app-marketplace closed-deal medians. Full math + comparable deal list on /methodology.
| 📺 Ad-supported base | 15× MRR |
| ⭐ ★ rating < 3.5 (weak) | -18% |
| 🏷 Medical category multiple | +12% |
Synthetic estimate from ratings × category benchmarks. Calibrated against 2024-2026 mobile-attribution retention + DAU/MAU reports. Numbers are US-storefront-equivalent — true global audience can be 5-10× larger for international apps. Full math + source list on /methodology.
| 📲 Medical engagement | ~55 installs / rating |
| 🔁 Medical D30 retention | 25% |
| 📍 DAU / MAU stickiness | 0.20 |
How we forecast this revenue
LOW CONFIDENCEBU Investment Matrix
Pre-traction · 34/100INDIE TIERlimited signal- 💰 Revenue: Marginal — $201 - $1256/mo · INDIE tier · medium confidence, trajectory unclear.
- ⭐ Quality: 3.27★ across 1,067 reviews — below category median.
- 📍 Market: Not yet charting in any of the 9 monitored markets.
- 📈 Growth: ⚠ last update 485d ago — possibly dormant.
- ⚠️ Risk: Elevated — dormant (485d since update).
💰 Forecast Revenue / mo
MODEL| Low install base (1,067 ratings)METRIC | +$1,500 | |
| Below-average rating (3.3★)METRIC | −$1,500 | |
| Mature app (12y old)METRIC | +$1,500 | |
| Ad-supported / freemiumMETRIC | +$600 |
📈 Reviews Growth
LIVE⭐ Rating Trend
LIVEProfile & Insights
Identification
- App name
- CANImmunize
- Developer
- CANImmunize Inc.
- Bundle ID
- ca.ohri.immunizeapp
- App Store URL
- Open in App Store
- Category
- Medical
- Content rating
- Not found
- Languages
- Not found
Company
- Website
- canimmunize.ca
- Tagline
- Not found
- Description
- Not found
- Founded
- Not found
- HQ / Address
- Not found
- Employees
- Not found
- Logo
- Not found
Revenue
- Verified revenue / mo
- Not found
- AI revenue estimate / mo
- Not found
- AI annual estimate
- Not found
- ML model estimate / mo
- $115/mo
- Top-grossing rank
- Not found
- All-time revenue
- Not found
- Pricing
- Not found
Founder
Funding
Press & Links
Contacts & Socials
📝 About this app
You can use CANImmunize to:
Track childhood, adult, and travel vaccinations for yourself and your family members.
Receive reminders about upcoming vaccinations right to your home screen.
Stay up-to-date with the vaccination schedule of your Canadian province or territory.
Create customized vaccination schedules for family members receiving travel or other types of vaccines.
Learn about outbreaks of vaccine-preventable diseases in your area.… View full description on the official store →
Tech & Domain Intel — canimmunize.ca
- Mail provider
- Google Workspace
- Tech stack
- Microsoft 365 · Apple Pay / Sign in with Apple · Google Workspace · SendGrid · AWS SES
Track this app’s revenue
FREE📝 Description
95
Why medium confidence: 1,067 ratings · no founder-verified revenue (model estimate only).



